A phase I study of samarium Sm-153 lexidronam combined with bortezomib for patients with relapsed or refractory multiple myeloma
Phase of Trial: Phase I
Latest Information Update: 18 Sep 2013
At a glance
- Drugs Bortezomib; Samarium-153-SM-lexidronam
- Indications Multiple myeloma
- Focus Adverse reactions
- 12 Dec 2006 Interim results have been reported.
- 22 Nov 2006 New trial record.